HK1213917A1 - 類霉素、組合物及相關方法 - Google Patents

類霉素、組合物及相關方法 Download PDF

Info

Publication number
HK1213917A1
HK1213917A1 HK16101839.5A HK16101839A HK1213917A1 HK 1213917 A1 HK1213917 A1 HK 1213917A1 HK 16101839 A HK16101839 A HK 16101839A HK 1213917 A1 HK1213917 A1 HK 1213917A1
Authority
HK
Hong Kong
Prior art keywords
disclosed
toxoids
toxins
methods
compositions
Prior art date
Application number
HK16101839.5A
Other languages
English (en)
Chinese (zh)
Inventor
Mark Shieh
Mike SOIKA
Original Assignee
Sanofi Pasteur, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50489432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1213917(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur, Inc. filed Critical Sanofi Pasteur, Inc.
Publication of HK1213917A1 publication Critical patent/HK1213917A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dermatology (AREA)
HK16101839.5A 2013-03-15 2014-03-14 類霉素、組合物及相關方法 HK1213917A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361793376P 2013-03-15 2013-03-15
US61/793,376 2013-03-15
PCT/US2014/029070 WO2014144594A1 (en) 2013-03-15 2014-03-14 Toxoid, compositions and related methods

Publications (1)

Publication Number Publication Date
HK1213917A1 true HK1213917A1 (zh) 2016-07-15

Family

ID=50489432

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101839.5A HK1213917A1 (zh) 2013-03-15 2014-03-14 類霉素、組合物及相關方法

Country Status (13)

Country Link
US (1) US20160030542A1 (enExample)
EP (1) EP2970400A1 (enExample)
JP (1) JP2016519671A (enExample)
KR (1) KR20150133771A (enExample)
CN (1) CN105308066A (enExample)
AR (1) AR095668A1 (enExample)
AU (2) AU2014228983B2 (enExample)
BR (1) BR112015023469A8 (enExample)
CA (1) CA2907156A1 (enExample)
HK (1) HK1213917A1 (enExample)
SG (1) SG11201507578PA (enExample)
TW (1) TW201518316A (enExample)
WO (1) WO2014144594A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
CN108003224A (zh) * 2017-12-20 2018-05-08 天康生物股份有限公司 一种多杀性巴氏杆菌毒素蛋白的纯化方法
US20250213667A1 (en) 2022-06-01 2025-07-03 Valneva Austria Gmbh Clostridium difficile vaccine
EP4658302A1 (en) 2023-02-02 2025-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071759A (en) * 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
JP2010534622A (ja) 2007-07-26 2010-11-11 サノフィ パストゥール リミテッド 抗原−アジュバント組成物および方法
CN101855336B (zh) * 2007-09-14 2019-07-30 赛诺菲巴斯德生物制剂有限责任公司 含艰难梭菌类毒素a和b的药物组合物
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection

Also Published As

Publication number Publication date
AR095668A1 (es) 2015-11-04
TW201518316A (zh) 2015-05-16
JP2016519671A (ja) 2016-07-07
AU2018204879A1 (en) 2018-07-26
KR20150133771A (ko) 2015-11-30
EP2970400A1 (en) 2016-01-20
US20160030542A1 (en) 2016-02-04
BR112015023469A2 (pt) 2017-07-18
WO2014144594A1 (en) 2014-09-18
WO2014144594A8 (en) 2014-11-13
BR112015023469A8 (pt) 2019-12-03
AU2014228983B2 (en) 2018-04-05
SG11201507578PA (en) 2015-10-29
AU2014228983A1 (en) 2015-10-08
CN105308066A (zh) 2016-02-03
CA2907156A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
EP4588521A3 (en) Polypeptide-antigen conjugates with non-natural amino acids
BRPI0816790A8 (pt) Composições farmacêuticas contendo toxóides a e b de clostridium difficile
MY193249A (en) Anti-human cd19 antibodies with high affinity
WO2011098962A3 (fr) Polysaccharides anioniques fonctionnalisés par au moins deux groupements hydrophobes portés par un spacer au moins trivalent
HK1213800A1 (zh) 類毒素、組合物及相關方法
WO2014178078A3 (en) Novel cloning, expression & purification method for the preparation of ranibizumab
WO2014107652A3 (en) Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
WO2011091376A3 (en) Immunogenic influenza composition
HK1213917A1 (zh) 類霉素、組合物及相關方法
MX2015010305A (es) Vacuna de combinacion para virus sincitial respiratorio e influenza.
EA201490258A1 (ru) Составы парентеральной норовирусной вакцины
WO2014017493A9 (ja) ワクチン
HK1225744A1 (zh) 制备高纯度的肉毒杆菌毒素神经毒性组分的方法及其应用
WO2012097116A3 (en) Isotopologues of isoindole derivatives
AU2014324961A8 (en) Highly potent glucocorticoids
IN2014DN09791A (enExample)
PH12016500360A1 (en) A bacterial vaccine and methods for manufacture thereof
PH12016502050B1 (en) Homovanillinic acid ester, in particular, for creating a hot and/or pungent taste sensation
IN2015DN03203A (enExample)
MY166879A (en) Attenuated swine influenza vaccines and methods of making and use thereof
MX2015017257A (es) Composiciones y metodos de inmunizar contra clostridium difficile.
WO2018071563A8 (en) Microorganisms and methods for the co-production of ethylene glycol and isobutene
EP3730148A3 (en) Immunogenic composition comprising mycoplasma antigens
MX364849B (es) Proceso para la preparacion de 5-fluorotriptofol.
WO2014100117A3 (en) Methods of using ion exchange chromatography to control levels of high mannose glycoforms